Literature DB >> 29891533

A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference.

John R Mills1, Mindy C Kohlhagen1, Maria A V Willrich1, Taxiarchis Kourelis2, Angela Dispenzieri1,2, David L Murray1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29891533     DOI： 10.1182/blood-2018-05-848986

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  11 in total

1.  MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins.

Authors:  Lauren M Moore; Sun Cho; Katie L Thoren
Journal:  Clin Chim Acta       Date:  2019-02-18       Impact factor: 3.786

Review 2.  Bringing mass spectrometry into the care of patients with multiple myeloma.

Authors:  David L Murray
Journal:  Int J Hematol       Date:  2022-04-26       Impact factor: 2.490

3.  Minimal residual disease in multiple myeloma: why, when, where.

Authors:  Andrew J Yee; Noopur Raje
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 4.  Antibody-Based Treatment Approaches in Multiple Myeloma.

Authors:  Hitomi Hosoya; Surbhi Sidana
Journal:  Curr Hematol Malig Rep       Date:  2021-03-17       Impact factor: 3.952

5.  Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy.

Authors:  Marion Eveillard; Neha Korde; Amanda Ciardiello; Benjamin Diamond; Alexander Lesokhin; Sham Mailankody; Eric Smith; Hani Hassoun; Malin Hultcrantz; Urvi Shah; Sydney Lu; Meghan Salcedo; Kelly Werner; Jenna Rispoli; Donna Mastey; Ola Landgren; Katie Thoren
Journal:  Clin Chim Acta       Date:  2021-02-02       Impact factor: 3.786

6.  The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.

Authors:  Nina Shah; Jack Aiello; David E Avigan; Jesus G Berdeja; Ivan M Borrello; Ajai Chari; Adam D Cohen; Karthik Ganapathi; Lissa Gray; Damian Green; Amrita Krishnan; Yi Lin; Elisabet Manasanch; Nikhil C Munshi; Ajay K Nooka; Aaron P Rapoport; Eric L Smith; Ravi Vij; Madhav Dhodapkar
Journal:  J Immunother Cancer       Date:  2020-07       Impact factor: 13.751

7.  MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients.

Authors:  Patrick W Mellors; Surendra Dasari; Mindy C Kohlhagen; Taxiarchis Kourelis; Ronald S Go; Eli Muchtar; Morie A Gertz; Shaji K Kumar; Francis K Buadi; Maria A V Willrich; John A Lust; Prashant Kapoor; Martha Q Lacy; David Dingli; Yi Hwa; Amie Fonder; Miriam Hobbs; Susan Hayman; Rahma Warsame; Nelson R Leung; Yi Lin; Wilson Gonsalves; Mustaqeem Siddiqui; Robert A Kyle; S Vincent Rajkumar; David L Murray; Angela Dispenzieri
Journal:  Blood Cancer J       Date:  2021-03-04       Impact factor: 11.037

8.  Sensitive multiple myeloma disease monitoring by mass spectrometry.

Authors:  Rasa Santockyte; Chelsea Jin; James Pratt; Ron Ammar; Keyur Desai; Mohan Bolisetty; Prianka Das; Mihaela Popa-McKiver; Oscar Puig
Journal:  Blood Cancer J       Date:  2021-04-29       Impact factor: 11.037

9.  Development of novel methods for non-canonical myeloma protein analysis with an innovative adaptation of immunofixation electrophoresis, native top-down mass spectrometry, and middle-down de novo sequencing.

Authors:  W Ian Deighan; Valerie J Winton; Rafael D Melani; Lissa C Anderson; John P McGee; Luis F Schachner; David Barnidge; David Murray; H Denis Alexander; David S Gibson; Michael J Deery; Feargal P McNicholl; Joseph McLaughlin; Neil L Kelleher; Paul M Thomas
Journal:  Clin Chem Lab Med       Date:  2020-10-20       Impact factor: 3.694

10.  Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report.

Authors:  David L Murray; Noemi Puig; Sigurdur Kristinsson; Saad Z Usmani; Angela Dispenzieri; Giada Bianchi; Shaji Kumar; Wee Joo Chng; Roman Hajek; Bruno Paiva; Anders Waage; S Vincent Rajkumar; Brian Durie
Journal:  Blood Cancer J       Date:  2021-02-01       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.